Global pharmaceutical company developing vaccines and medicines for oncology, inflammation, cardiovascular, and rare diseases including COVID-19 vaccine.
Profile & Fundamentals
Pfizer: Company identity, ownership, reported financial performance, balance sheets, and corporate actions.
Profile & Fundamentals
Pfizer Profile & Fundamentals
Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.
Explore this pageJump to a Profile & Fundamentals section
Explore this research
Profile & Fundamentals contents
Jump directly to any section
Company and Market Context
Company Profile & Ownership
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Company profile record
Pfizer Inc
Common Stock · Health Care · Pharmaceuticals
Company
- Company / asset
- Pfizer Inc
- Security type
- Common Stock
- Sector
- Health Care
- Industry
- Pharmaceuticals
- HQ
- 🇺🇸 United States
- Head office
- 66 Hudson Boulevard East, New York, NY, United States, 10001-2192
Leadership & scale
- Chief executive
- Dr. Albert Bourla D.V.M., Ph.D.
- CEO year born
- 1962
- Full-time employees
- 75K
- Fiscal year end
- December
- IPO date
- 1942-06-22
Fundamentals snapshot
- Market Cap
- USD 156.7B
- P/E
- 36.2x
- Revenue (Q2 26)
- USD 15.0B
- Profit (Q2 26)
- USD -246.0M
- Dividend Yield
- 4.4%
- Revenue (FY 25)
- USD 62.6B
- Shares in public float
- 5.7B
- Insider ownership
- 0.1%
Reporting & identifiers
- Symbol
- PFE.NYSE
- Listing
- 🇺🇸 United States | Dividend Tax: 30%
- Ticker Currency
- USD
- Income Statement Currency
- USD
- Balance Sheet Currency
- USD
- Cash Flow Currency
- USD
- EPS Currency
- USD
- Contract Type
- SPOT
- ISIN
- US7170811035
- Asset ID
- equity_6450e9e7-4c57-5c72-97d1-057751df8e53
Ownership
Shares Outstanding
Latest: 5.7B | Max: 6.1B | Min: 5.6B
Latest reported ownership snapshot
As of Oct 1, 2026Float Shares
99.88%
5.7B latest reported shares
Insider Ownership
0.10%
Latest reported insider stake
Short Float
0.03%
Latest reported short interest / float
Top Holders
Source tablesView ownership tables
Shares Outstanding
Annual reported shares outstanding; up to 10 reporting dates.
Scroll the table to see every column.
| Reporting date | Shares outstanding |
|---|---|
| 2017-01-01 | 6,064,000,000 |
| 2018-01-01 | 5,788,000,000 |
| 2019-01-01 | 5,631,000,000 |
| 2020-01-01 | 5,662,000,000 |
| 2021-01-01 | 5,768,000,000 |
| 2022-01-01 | 5,743,000,000 |
| 2023-01-01 | 5,647,000,000 |
| 2024-01-01 | 5,703,000,000 |
| 2025-01-01 | 5,686,000,000 |
| 2026-01-01 | 5,699,000,000 |
Top Holders
Available reported ownership records.
Scroll the table to see every column.
| Holder | Shares | Ownership | Reported date |
|---|---|---|---|
| BlackRock Inc | 498,257,550 | 8.74% | 2026-03-31 |
| Vanguard Capital Management, LLC | 369,430,012 | 6.48% | 2026-03-31 |
| State Street Corp | 301,589,865 | 5.29% | 2026-03-31 |
| Vanguard MStar Total Stk Mkt Idx Invest | 181,148,109 | 3.18% | 2026-08-31 |
| Vanguard 500 Index Investor | 151,423,159 | 2.66% | 2026-08-31 |
| Geode Capital Management, LLC | 133,561,742 | 2.34% | 2026-03-31 |
| Vanguard Portfolio Management, LLC | 116,734,695 | 2.05% | 2026-03-31 |
| Fisher Asset Management, LLC | 109,067,291 | 1.91% | 2026-06-30 |
| Morgan Stanley - Brokerage Accounts | 92,685,370 | 1.63% | 2026-03-31 |
| iShares Core S&P 500 ETF | 75,864,389 | 1.33% | 2026-08-31 |
| Fidelity 500 Index | 73,699,750 | 1.29% | 2026-07-31 |
| State Street® SPDR® S&P 500® ETF | 69,817,535 | 1.23% | 2026-08-31 |
| Northern Trust Corp | 62,026,552 | 1.09% | 2026-03-31 |
| NORGES BANK | 61,505,586 | 1.08% | 2026-06-30 |
| Massachusetts Financial Services Company | 56,911,830 | 1% | 2026-03-31 |
Earnings, Profitability & Valuation
Earnings, Profitability & Valuation
Earnings & Revenue
Earnings and Revenue Trajectory
AI Review
Pfizer's financial story is one of operational stabilization following the post-pandemic vaccine unwind. Headline revenue stabilized near sixty-three point seven billion dollars for the trailing twelve months through mid-2026, demonstrating that non-COVID medicines are growing steadily. Although accounting results showed a net loss in the second quarter of 2026 due to a four-point-three-billion-dollar non-cash clinical trial impairment, core operating income remained resilient at nearly sixteen billion dollars. This gap reveals that actual cash generation is significantly healthier than reported net losses suggest. Trailing free cash flow reached eleven billion dollars, providing crucial liquidity to self-fund operations and protect shareholder distributions as legacy patent expirations approach.
Pfizer's financial story is one of operational stabilization following the post-pandemic vaccine unwind. Headline revenue stabilized near sixty-three point seven billion dollars for the trailing twelve months through mid-2026, demonstrating that non-COVID medicines are growing steadily. Although accounting results showed a net loss in the second quarter of 2026 due to a four-point-three-billion-dollar non-cash clinical trial impairment, core operating income remained resilient at nearly sixteen billion dollars. This gap reveals that actual cash generation is significantly healthier than reported net losses suggest. Trailing free cash flow reached eleven billion dollars, providing crucial liquidity to self-fund operations and protect shareholder distributions as legacy patent expirations approach.
Revenue, Net Income, and Free Cash Flow
Latest: USD 62.6B | Max: USD 100.3B | Min: USD 2.1B
Valuation
P/E Ratio (TTM)iPublished valuation snapshots use the earnings basis recorded with each observation. Source tables retain that basis.
Latest: 18x
Profitability & Margins
Margins and Operating Efficiency
AI Review
Profitability is rebounding after absorbing pandemic-related disruptions. Gross margins expanded to seventy point three percent in fiscal 2025, recovering from fifty point nine percent in 2023 as low-margin vaccine inventories cleared and sales shifted toward high-margin cancer biologics. Operating margins stabilized near twenty-five percent, directly supported by ongoing corporate cost-reduction programs. This margin pattern demonstrates underlying pricing power across specialized treatments. Enterprise restructuring initiatives targeting billions in cumulative operational savings provide vital operating leverage. This disciplined cost containment creates a durable cushion that protects profitability even as mature small-molecule drugs encounter generic price competition.
Profitability is rebounding after absorbing pandemic-related disruptions. Gross margins expanded to seventy point three percent in fiscal 2025, recovering from fifty point nine percent in 2023 as low-margin vaccine inventories cleared and sales shifted toward high-margin cancer biologics. Operating margins stabilized near twenty-five percent, directly supported by ongoing corporate cost-reduction programs. This margin pattern demonstrates underlying pricing power across specialized treatments. Enterprise restructuring initiatives targeting billions in cumulative operational savings provide vital operating leverage. This disciplined cost containment creates a durable cushion that protects profitability even as mature small-molecule drugs encounter generic price competition.
Profitability Margins
Latest: 70.3% | Max: 71.7% | Min: 3.6%
Latest Profitability Ratios as of 2025-12-31
Gross Margin
70.3%
Gross profit / revenue
Operating Margin
24.7%
Operating income / revenue
Net Margin
12.4%
Net income / revenue
FCF Margin
14.5%
Free cash flow / revenue
Source tablesView earnings, profitability & valuation tables
Revenue, Net Income, and Free Cash Flow
Annual reported results, using the source statement's recorded USD conversion. Up to 10 reporting periods; missing values are not estimated.
Scroll the table to see every column.
| Period end | Revenue (USD) | Net income (USD) | Free cash flow (USD) |
|---|---|---|---|
| 2016-12-31 | 52,824,000,000 | 7,215,000,000 | 13,902,000,000 |
| 2017-12-31 | 52,546,000,000 | 21,305,000,000 | 14,253,000,000 |
| 2018-12-31 | 53,647,000,000 | 11,153,000,000 | 13,631,000,000 |
| 2019-12-31 | 41,172,000,000 | 16,273,000,000 | 9,994,000,000 |
| 2020-12-31 | 41,651,000,000 | 9,159,000,000 | 11,612,000,000 |
| 2021-12-31 | 81,288,000,000 | 22,147,000,000 | 29,869,000,000 |
| 2022-12-31 | 100,330,000,000 | 31,365,000,000 | 26,031,000,000 |
| 2023-12-31 | 59,553,000,000 | 2,133,000,000 | 4,793,000,000 |
| 2024-12-31 | 63,627,000,000 | 8,020,000,000 | 9,835,000,000 |
| 2025-12-31 | 62,579,000,000 | 7,770,000,000 | 9,076,000,000 |
Published P/E Ratio
Published valuation snapshots retain each observation's earnings basis.
Scroll the table to see every column.
| Period end | P/E (times earnings) | Earnings basis |
|---|---|---|
| 2025-12-31 | 18.22 | Trailing four quarters |
| 2024-12-31 | 18.87 | Trailing four quarters |
| 2023-12-31 | 76.26 | Trailing four quarters |
| 2022-12-31 | 9.38 | Annual net income |
| 2021-12-31 | 15.38 | Annual net income |
Profitability Margins
Matching annual reporting dates. Values are percentages.
Scroll the table to see every column.
| Period end | Gross margin (%) | Operating margin (%) | Net margin (%) | Free cash flow margin (%) |
|---|---|---|---|---|
| 2016-12-31 | 69.8 | 27.02 | 13.66 | 26.32 |
| 2017-12-31 | 69.97 | 27.39 | 40.55 | 27.12 |
| 2018-12-31 | 70.16 | 28.5 | 20.79 | 25.41 |
| 2019-12-31 | 69.34 | 18.24 | 39.52 | 24.27 |
| 2020-12-31 | 71.74 | 21.81 | 21.99 | 27.88 |
| 2021-12-31 | 57.67 | 25.58 | 27.25 | 36.74 |
| 2022-12-31 | 61.89 | 37.43 | 31.26 | 25.95 |
| 2023-12-31 | 50.95 | 8.89 | 3.58 | 8.05 |
| 2024-12-31 | 65.77 | 25.91 | 12.6 | 15.46 |
| 2025-12-31 | 70.33 | 24.67 | 12.42 | 14.5 |
Public data excerpt created by iPulse AI and published by Future Edge Group FZE. Source: eodhd. Snapshot retrieved 2026-09-29.
Use is subject to the iPulse AI Terms of Service and applicable source rights. Missing inputs are not estimated. Full access includes the remaining records, research and interactive tools.
Complete Research Workspace
Unlock the complete Profile & Fundamentals
Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.